No Data
Qyuns Therapeutics Gets China Nod to Add Pediatric Plaque Psoriasis Indication to Drug
Qyuns Therapeutics' Clinical Study of Anti-Inflammatory Injection for Spinal Joints Shows Positive Results
Chuangxin Biotechnology-B (02509): The Phase III clinical trial of QX002N for the treatment of ankylosing spondylitis has reached its primary endpoint.
QX002N injection, developed independently by Quanxin Biotechnology-B (02509), has been announced for the treatment of ankylosing spondylitis...
Express News | Qyuns Therapeutics Co Ltd - Phase III Clinical Trial of QX002N for Ankylosing Spondylitis Reaches Primary Endpoint
Chunshin Biotech-B (02509.HK): The application and supplementary application for the market approval of QX001S (Ustinumab injection) for Crohn's disease have been accepted.
On February 12, 2023, GLONG announced that on February 11, 2025, the marketing license application and supplement application for Ustekinumab injection (intravenous infusion) and Ustekinumab injection (research code: QX001S/HDM3001-2) for Crohn's disease was accepted. QX001S is a biosimilar to the original product Stelara (Ustekinumab injection), which works by blocking the binding of the shared p40 subunit of IL-12 and IL-23 to the IL-12Rβ1 receptor protein on target cells.
Express News | Qyuns Therapeutics - Acceptance of Marketing Authorisation Application and Supplemental Application for QX001S Injection for Crohn's Disease
